ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • [18F]FDG PET
  • #N/A
  • 18FDG PET/CT scan
  • 18FDG PET/CT scan and Angiography
  • 18FDG PET/CT scan and cardiac involvement
  • 18FDG PET/CT scan and diagnostic imaging
  • 18FDG PET/CT scan and Musculoskeletal
  • 18FDG PET/CT scan and polymyalgia rheumatica
  • 24-hour activity profile
  • 25 OH D Vitamin insufficiency
  • 25-hydroxyvitamin D
  • 25-hydroxyvitamin D and cardiovascular disease
  • 25-hydroxyvitamin D and hypercalcemia
  • 25-hydroxyvitamin D and pregnancy
  • 25-hydroxyvitamin D and rheumatoid arthritis (RA)
  • 25-hydroxyvitamin D and Vitamin D
  • 3D model
  • 3D model and arthritis
  • 3D model and inflammation
  • 5-HT
  • 8-hydroxydeoxyguanine and DNA
  • A3 Adenosine receptor and gout
  • AA-amyloidosis
  • AA-amyloidosis and familial Mediterranean fever
  • AA-amyloidosis and proteinuria
  • AAV and Diagnostic Tests
  • abaloparatide
  • Abatacept
  • Abatacept and adult-onset Still's disease
  • abatacept and anti-citrullinated protein/peptide antibodies (ACPA)
  • abatacept and anti-TNF therapy
  • Abatacept and autoantibodies
  • abatacept and biomarkers
  • Abatacept and body mass
  • Abatacept and health care cost
  • abatacept and histopathologic
  • Abatacept and juvenile idiopathic arthritis (JIA)
  • Abatacept and macrophages
  • abatacept and magnetic resonance imaging (MRI)
  • abatacept and matrix metalloproteinase (MMP)
  • abatacept and monocytes
  • abatacept and patient-reported outcome measures
  • Abatacept and psoriatic arthritis
  • abatacept and remission
  • abatacept and rheumatoid arthritis
  • Abatacept and rheumatoid arthritis (RA)
  • abatacept and rituximab
  • abatacept and tocilizumab
  • abatacept and treatment
  • Abatacept and tuberculosis
  • abatacept and tumor necrosis factor (TNF)
  • abatacept and ultrasonography
  • ABC and auto-immunity
  • ABP 798 and biosimilars
  • absenteeism
  • Abstracts
  • academic
  • academics
  • Access to care
  • access to care and Electronic Health Record
  • access to care and health disparities
  • access to care and high risk
  • Access to care and inflammatory arthritis
  • Access to care and lupus nephritis
  • access to care and medication
  • access to care and physical therapy
  • access to care and population studies
  • Access to care and primary care
  • Access to care and quality measures
  • Access to care and quality of care
  • access to care and remission
  • Access to care and rheumatologic disease
  • access to care and standards of care
  • Access to care and systemic lupus erythematosus (SLE)
  • accommodation
  • Accreditation
  • ACE
  • ACE-inhibitors
  • ACPA
  • ACPA and cardiovascular disease
  • ACPA and Early Rheumatoid Arthritis
  • ACPA and lung
  • ACPA and osteoclastogenesis
  • ACPA and palindromic rheumatism
  • ACPA and Periodontitis
  • ACPA and psoriatic arthritis
  • ACPA and RANK/RANKL pathway
  • ACPA and rheumatoid arthritis (RA)
  • ACR
  • ACR 20
  • ACR and C-reactive protein (CRP)
  • ACR and Health Assessment Questionnaire
  • ACR and rheumatoid arthritis (RA)
  • ACS and WOMAC
  • Activation triggers
  • activation triggers and dendritic cells
  • active patients and stable patients
  • activities
  • activities of daily living (ADL)
  • activities of daily living (ADL) and myositis
  • activities of daily living (ADL) and systemic sclerosis
  • activity limitation and activity restriction
  • Activity score
  • Activity score and ankylosing spondylitis (AS)
  • activity score and anti-dsDNA
  • activity score and assessment
  • activity score and biomarkers
  • activity score and classification criteria
  • activity score and patient outcomes
  • Activity score and patient questionnaires
  • activity score and patient-reported outcome measures
  • Activity score and polychondritis
  • activity score and polymyalgia rheumatica
  • activity score and prolactin
  • Activity score and psoriatic arthritis
  • activity score and remission
  • Activity score and rheumatoid arthritis (RA)
  • activity score and Still's disease
  • Activity score and systemic lupus erythematosus (SLE)
  • activity score and systemic sclerosis
  • Activity score and total joint replacement
  • activity score and treatment
  • Activity score and uveitis
  • acupressure and clinical trials
  • acupuncture
  • acupuncture and pediatrics
  • acute coronary syndrome (ACS) and left ventricular dysfunction (LVEF)
  • Acute-phase reactants
  • Acute-phase reactants and ankylosing spondylitis (AS)
  • acute-phase reactants and familial Mediterranean fever
  • acute-phase reactants and Janus kinase (JAK)
  • acute-phase reactants and rheumatoid arthritis (RA)
  • acylcarnitines
  • Adalimumab
  • adalimumab and ankylosing spondylitis (AS)
  • adalimumab and anti-CCP antibodies
  • adalimumab and anti-citrullinated protein/peptide antibodies (ACPA)
  • adalimumab and apoptosis
  • Adalimumab and biosimilars
  • adalimumab and economics
  • Adalimumab and health care cost
  • adalimumab and inflammatory arthritis
  • Adalimumab and inflammatory bowel disease (IBD)
  • adalimumab and interleukins (IL)
  • Adalimumab and juvenile arthritis
  • Adalimumab and juvenile idiopathic arthritis (JIA)
  • adalimumab and juvenile idiopathic arthritis-enthesitis (ERA)
  • Adalimumab and juvenile spondylarthropathy
  • adalimumab and matrix metalloproteinase (MMP)
  • adalimumab and messenger RNA (mRNA)
  • adalimumab and methotrexate (MTX)
  • Adalimumab and psoriatic arthritis
  • Adalimumab and rheumatoid arthritis
  • adalimumab and rheumatoid arthritis (RA)
  • Adalimumab and spondylarthritis
  • Adalimumab and spondylarthropathy
  • adalimumab and support
  • Adalimumab and uveitis
  • adam17
  • adaptive immunity
  • adaptive immunity and Cell Signaling
  • adaptive immunity and cutaneous lupus erythematosus
  • adenosine
  • adenosine deaminase 2 and Autoinflammatory Disease
  • Adenosine receptors
  • adenosine receptors and atp
  • Adenosine receptors and collagen
  • adenosine receptors and endothelial cells
  • adenosine receptors and IL-6
  • adenosine receptors and Netrin-1
  • adenosine receptors and osteoblasts
  • Adenosine receptors and osteoclastogenesis
  • adenosine receptors and prosthesis
  • Adenosine receptors and rheumatoid arthritis (RA)
  • adenosine receptors and salivary hypofunction
  • Adenosine receptors and scleroderma
  • adenosine receptors and Sema4D
  • adherence
  • Adherence Barrier
  • Adhesion molecules
  • adhesion molecules and epigenetics
  • Adhesion molecules and inflammation
  • adhesion molecules and monocytes
  • adhesion molecules and neutrophils
  • adhesion molecules and rheumatoid arthritis (RA)
  • adhesion molecules and signal transduction
  • Adhesion, Adhesion molecules
  • adhesive capsulitis
  • Adipocytokines
  • Adipocytokines and rheumatoid arthritis (RA)
  • Adipocytokines and systemic lupus erythematosus (SLE)
  • Adipocytokines and systemic sclerosis
  • Adipokines
  • adipokines and biomarkers
  • Adipokines and osteoarthritis
  • adipokines and rheumatoid arthritis
  • Adipokines and rheumatoid arthritis (RA)
  • adipose tissue
  • adipose tissue and adipokines
  • adipose tissue and bone density
  • [1]
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology